COPD News Today Home | COPD News Today
WEBSep 18, 2024 · Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by ...
1st approved Symbicort generic, Breyna, now available in US
WEBAug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 …
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
WEBby Joana Carvalho, PhD June 30, 2020. Breztri Aerosphere, AstraZeneca ’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of …
Tezepelumab wins breakthrough designation for eosinophilic COPD
WEBAug 12, 2024 · An eosinophilic profile refers to high blood levels of eosinophils, a type of immune cell. Abnormally high eosinophil counts have been linked to type 2 inflammation, which may contribute to lung inflammation in COPD and asthma.. The designation was announced in a press release by Amgen, which is developing tezepelumab with AstraZeneca.. The FDA’s breakthrough therapy designation is designed ...
FDA delays decision on Dupixent for COPD until September
WEBJun 3, 2024 · The U.S. Food and Drug Administration (FDA) has delayed by three months its decision about whether to approve Dupixent (dupilumab) as an add-on treatment for certain adults with chronic obstructive pulmonary disease (COPD). A decision is now expected by Sept. 27. An initial call was due at the end of this month, but the FDA said it …
Dupixent found to prevent COPD exacerbations in Phase 3 trial
WEBApr 3, 2023 · Dupixent shows promise for treating COPD “COPD is an urgent global health concern and a notoriously difficult-to-treat disease due to its heterogeneity, with no novel treatments approved in more than a decade,” George D. Yancopoulos, MD, PhD, president and chief scientific officer at Regeneron, and one of Dupixent’s inventors, said in a …
Trelegy Ellipta Reduces COPD Exacerbations and Improves Lung …
WEBApr 24, 2018 · Results revealed that treatment with the triple therapy Trelegy Ellipta significantly reduced the number of COPD hospitalizations due to severe exacerbations by 34% compared to Anoro Ellipta. Compared to Breo Ellipta, the reduction was of 13%, but this difference was not statistically significant. The …
Dupixent shown to reduce COPD exacerbations in 2nd clinical trial
WEBDec 4, 2023 · Dupixent use also resulted in better lung function for these COPD patients, per an interim analysis of the NOTUS study (NCT04456673), which is expected to conclude in 2024.. The positive findings were robust enough for them to be considered the result of a main analysis, according to the therapy’s developers Sanofi and Regeneron Pharmaceuticals.The companies expect to present detailed trial ...
COPD Patients See Quality of Life, Flare-up Changes With …
WEBApr 7, 2022 · The findings are from a Phase 2a trial, called COPD-ST2OP (NCT03615040), that investigated how safe astegolimab is and how well it works to reduce episodes of symptom worsening, called flare-ups, in patients with moderate-to-very severe COPD.Those given astegolimab also saw a reduction in flare-up frequency, although it was not significant compared to those on a placebo.
Phase 1 Study of COPD Therapy Completed; Phase 2 Set for This …
WEBMay 19, 2022 · Phase 1 Study of EP395 Completed; Phase 2 Trial Planned for This Year. by Marisa Wexler, MS May 19, 2022. A first-in-human clinical trial testing the safety and tolerability of EP395, EpiEndo Pharmaceuticals ’ experimental treatment for chronic obstructive pulmonary disease (COPD), is now finished. …